Stebas Tookad US FDA Panel To Weigh Novel Endpoints Missing Data And Toxicities

Steba’s Tookad: US FDA Panel To Weigh Novel Endpoints, Missing Data And Toxicities

11:57 EST 24 Feb 2020 | SCRIP

Sponsor seeks accelerated approval for low-risk, early-stage prostate cancer based on a trial that met its coprimary endpoints, but agency...